Literature DB >> 33499746

Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention.

Aaron S Devanathan1, Angela D M Kashuba1,2.   

Abstract

The persistence of HIV in the spleen, despite combination antiretroviral therapy, is not well understood. Sustained immune dysregulation and delayed immune recovery, in addition to immune cell exhaustion, may contribute to persistence of infection in the spleen. Eliminating HIV from this secondary lymphoid organ will require a thorough understanding of antiretroviral (ARV) pharmacology in the spleen, which has been minimally investigated. Low ARV exposure within the spleen may hinder the achievement of a functional or sterilizing cure if cells are not protected from HIV infection. In this study, we provide an overview of the anatomy and physiology of the spleen, review the evidence of the spleen as a site for persistence of HIV, discuss the consequences of persistence of HIV in the spleen, address challenges to eradicating HIV in the spleen, and examine opportunities for future curative efforts.

Entities:  

Keywords:  HIV; antiretrovirals; persistence; pharmacology; reservoirs; spleen

Mesh:

Substances:

Year:  2021        PMID: 33499746      PMCID: PMC8573804          DOI: 10.1089/AID.2020.0266

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   1.723


  125 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

Review 2.  HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities.

Authors:  Corbin G Thompson; Cynthia L Gay; Angela D M Kashuba
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-16       Impact factor: 2.205

Review 3.  Monoclonal antibody therapeutics: history and future.

Authors:  Nicholas A P S Buss; Simon J Henderson; Mary McFarlane; Jacintha M Shenton; Lolke de Haan
Journal:  Curr Opin Pharmacol       Date:  2012-08-21       Impact factor: 5.547

4.  The spleen in acquired immunodeficiency syndrome (AIDS).

Authors:  S Falk; H Müller; H J Stutte
Journal:  Pathol Res Pract       Date:  1988-08       Impact factor: 3.250

5.  Comparative aspects of splenic microcirculatory pathways in mammals: the region bordering the white pulp.

Authors:  E E Schmidt; I C MacDonald; A C Groom
Journal:  Scanning Microsc       Date:  1993-06

6.  Ability of unstimulated and phorbol-ester-stimulated human blood-monocyte-derived macrophages to metabolize drugs and its implications.

Authors:  S N Wickramasinghe; G Barden; B Gardner
Journal:  Clin Lab Haematol       Date:  1991

7.  Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection.

Authors:  Jacob D Estes; Qingsheng Li; Matthew R Reynolds; Stephen Wietgrefe; Lijie Duan; Timothy Schacker; Louis J Picker; David I Watkins; Jeffrey D Lifson; Cavan Reilly; John Carlis; Ashley T Haase
Journal:  J Infect Dis       Date:  2006-01-30       Impact factor: 5.226

8.  Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.

Authors:  William A Lee; Gong-Xin He; Eugene Eisenberg; Tomas Cihlar; Swami Swaminathan; Andrew Mulato; Kenneth C Cundy
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

9.  Multidrug transporter activity in lymphocytes.

Authors:  James I Elliott; Selina Raguz; Christopher F Higgins
Journal:  Br J Pharmacol       Date:  2004-10-18       Impact factor: 8.739

10.  The spleen in HIV infection--morphological evidence of HIV-associated macrophage dysfunction.

Authors:  S Falk; H J Stutte
Journal:  Res Virol       Date:  1990 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.